TimesSquare Capital Management LLC Purchases 8,840 Shares of argenx SE (NASDAQ:ARGX)

TimesSquare Capital Management LLC lifted its position in argenx SE (NASDAQ:ARGX) by 8.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 109,490 shares of the company’s stock after buying an additional 8,840 shares during the period. TimesSquare Capital Management LLC’s holdings in argenx were worth $59,352,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its holdings in shares of argenx by 49.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,504,506 shares of the company’s stock worth $2,167,235,000 after acquiring an additional 1,830,651 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of argenx by 24.8% in the 1st quarter. Janus Henderson Group PLC now owns 2,216,648 shares of the company’s stock valued at $872,690,000 after purchasing an additional 439,889 shares during the period. Avoro Capital Advisors LLC increased its stake in argenx by 0.3% during the 1st quarter. Avoro Capital Advisors LLC now owns 1,238,467 shares of the company’s stock worth $487,609,000 after purchasing an additional 3,900 shares in the last quarter. Clearbridge Investments LLC raised its holdings in argenx by 3.6% during the 2nd quarter. Clearbridge Investments LLC now owns 617,466 shares of the company’s stock worth $265,535,000 after buying an additional 21,189 shares during the period. Finally, Sei Investments Co. lifted its stake in argenx by 15.2% in the second quarter. Sei Investments Co. now owns 381,544 shares of the company’s stock valued at $164,079,000 after buying an additional 50,477 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on ARGX. Wedbush raised their price objective on shares of argenx from $519.00 to $560.00 and gave the stock an “outperform” rating in a report on Friday, July 26th. Raymond James restated a “strong-buy” rating and issued a $605.00 price target on shares of argenx in a report on Thursday, October 10th. Deutsche Bank Aktiengesellschaft downgraded argenx from a “buy” rating to a “hold” rating in a report on Friday, October 4th. Truist Financial boosted their target price on argenx from $540.00 to $660.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, JPMorgan Chase & Co. raised their price target on shares of argenx from $640.00 to $670.00 and gave the stock an “overweight” rating in a research note on Monday, November 4th. Four research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $615.50.

argenx Stock Performance

Shares of NASDAQ:ARGX opened at $596.00 on Friday. argenx SE has a 52-week low of $327.73 and a 52-week high of $611.22. The company has a market capitalization of $35.64 billion, a P/E ratio of -677.27 and a beta of 0.61. The company has a 50-day simple moving average of $547.05 and a 200 day simple moving average of $474.44.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. The company had revenue of $588.88 million during the quarter, compared to analysts’ expectations of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same period last year, the firm posted ($1.25) earnings per share. As a group, equities analysts forecast that argenx SE will post 2.2 earnings per share for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.